OTC · LFLY
Leafly Holdings, Inc.
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
Loading market information…
NASDAQ · TFFP · USD
Stock price, earnings
Quote as of Dec 12, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TFF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow TFF Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals, Inc., leverages its proprietary Thin Film Freezing (TFF) technology platform for the advancement and commercialization of therapeutic products across the United States and Australia. A primary emphasis is placed on creating inhaled dry powder formulations to address various pulmonary ailments and disorders. Its two leading drug candidates, both currently in Phase II clinical trials, include TFF Voriconazole Inhalation Powder, designed to combat invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, aimed at preventing lung transplant rejection. Beyond these, the company's pipeline features other dry powder products like a cannabidiol substance targeting various epilepsy syndromes, anxiety, insomnia, and pain; an Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 patients; Niclosamide Inhalation Powder, intended for human tapeworm infections and COVID-19; and a range of other vaccines. Strategic partnerships are also central to its operations, including a licensing arrangement with the University of Texas at Austin for inhaled dry powder drug development, a joint development pact with Augmenta Bioworks, Inc. for the inhaled SARS-CoV2 monoclonal antibody, and a broad licensing and collaboration agreement with UNION therapeutics A/S. Established in 2018, the company maintains its headquarters in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $333.35K+376.22% vs estimate |
| Q1 2023 | May 11, 2023 | -$4.75+5.0% vs estimate | $51.43K-79.43% vs estimate |
|---|
| Q4 2022 | Mar 7, 2023 | -$0.10+58.33% vs estimate | $300.00K+900.0% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.86-$0.05 (-5.91%)
Phio Pharmaceuticals Corp.’s quoted price sits in the lower half of its reported 52-week range, 79.41% below the high.
$0.47$0.00 (0.0%)
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
$0.50$0.00 (0.0%)
TC Biopharm (Holdings) Plc’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
$0.37$0.00 (0.0%)
Seelos Therapeutics, Inc.: Healthcare · Biotechnology.
$0.16+$0.02 (+12.4%)
Virios Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
$0.31+$0.08 (+36.94%)
Akerna Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.46% below the high.
